Phosphatidylinositol 4-kinases: Function, structure, and inhibition
Language English Country United States Media print-electronic
Document type Journal Article, Research Support, Non-U.S. Gov't, Review
PubMed
26183104
DOI
10.1016/j.yexcr.2015.03.028
PII: S0014-4827(15)00232-3
Knihovny.cz E-resources
- Keywords
- Crystal structure, Inhibitor, Phosphatidylinositol 4-kinase, Virus,
- MeSH
- 1-Phosphatidylinositol 4-Kinase antagonists & inhibitors metabolism MeSH
- Antiviral Agents pharmacology MeSH
- Cell Membrane metabolism MeSH
- Humans MeSH
- trans-Golgi Network drug effects MeSH
- Protein Transport drug effects MeSH
- Animals MeSH
- Check Tag
- Humans MeSH
- Animals MeSH
- Publication type
- Journal Article MeSH
- Research Support, Non-U.S. Gov't MeSH
- Review MeSH
- Names of Substances
- 1-Phosphatidylinositol 4-Kinase MeSH
- Antiviral Agents MeSH
The phosphatidylinositol 4-kinases (PI4Ks) synthesize phosphatidylinositol 4-phosphate (PI4P), a key member of the phosphoinositide family. PI4P defines the membranes of Golgi and trans-Golgi network (TGN) and regulates trafficking to and from the Golgi. Humans have two type II PI4Ks (α and β) and two type III enzymes (α and β). Recently, the crystal structures were solved for both type II and type III kinase revealing atomic details of their function. Importantly, the type III PI4Ks are hijacked by +RNA viruses to create so-called membranous web, an extensively phosphorylated and modified membrane system dedicated to their replication. Therefore, selective and potent inhibitors of PI4Ks have been developed as potential antiviral agents. Here we focus on the structure and function of PI4Ks and their potential in human medicine.
References provided by Crossref.org
Crystal Structure of the ORP8 Lipid Transport ORD Domain: Model of Lipid Transport
The 14-3-3 Proteins as Important Allosteric Regulators of Protein Kinases
Discovery of the Hedgehog Pathway Inhibitor Pipinib that Targets PI4KIIIß
PI(4,5)P2 controls plasma membrane PI4P and PS levels via ORP5/8 recruitment to ER-PM contact sites
Purine analogs as phosphatidylinositol 4-kinase IIIβ inhibitors